Global Collaboration Evive Biotech operates across the US, Singapore, and China with a strategy to bring innovative therapies from China to the world, presenting multiple international partnership opportunities for biopharma, academia, and CROs seeking global reach.

Biotech Focus Strong emphasis on novel biological therapies spanning oncology, inflammatory and metabolic diseases creates potential for partnerships in antibody discovery, early-stage drug candidates, and platform licensing with serviceable revenue through collaborations and co-development.

Growth & Funding With revenue in the mid tens of millions and funding of seventy million, Evive shows financial flexibility for strategic alliances, joint ventures, or milestone-based collaborations to accelerate development and market access.

Regulatory & Market Access In-house regulatory expertise and international management experience position Evive as a favorable partner for streamlined regulatory strategy, global filings, and accelerated pathways in multiple regions.

Recent Partnerships Recent collaborations with Nonabio and Nona Biosciences indicate active interest in antibody discovery partnerships, signaling openness to co-development and technology licensing opportunities that can be explored for expanding the pipeline.